United Therapeutics Corporation (UTHR) Price CAGR:90.89%(TTM)
Over the latest trailing 12-month period, United Therapeutics Corporation (UTHR)'s price cagr is +90.89%. The comparable SPY value is +22.87%. Year-to-date price return is +9.91%. Price CAGR uses adjusted close price history and excludes dividends.
Over longer horizons, United Therapeutics Corporation's Price CAGR averages 33.80% over 3 years and 24.96% over 5 years. The price CAGR (Compound Annual Growth Rate) shows how United Therapeutics Corporation's stock price has grown over various time periods. This measures pure price appreciation without including dividends.
UTHR Price CAGR Chart
United Therapeutics Corporation (UTHR)
UTHR Quarterly Price (YoY)
Price growth vs the same quarter one year earlier, last 20 quarters.
UTHR Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | 317.05 | 290.39 | -26.66 | -8.41% | -8.41% |
| 2024 | 220.75 | 317.05 | +96.30 | +43.62% | +43.62% |
| 2023 | 238.29 | 220.75 | -17.54 | -7.36% | -7.36% |
| 2022 | 177.00 | 238.29 | +61.29 | +34.63% | +34.63% |
| 2021 | 119.96 | 177.00 | +57.04 | +47.55% | +47.55% |
| 2020 | 78.06 | 119.96 | +41.90 | +53.68% | +53.68% |
| 2019 | 108.46 | 78.06 | -30.40 | -28.03% | -28.03% |
| 2018 | 130.94 | 108.46 | -22.48 | -17.17% | -17.17% |
| 2017 | 98.33 | 130.94 | +32.61 | +33.16% | +33.16% |
| 2016 | 175.43 | 98.33 | -77.10 | -43.95% | -43.95% |
| 2015 | 88.03 | 175.43 | +87.40 | +99.28% | +99.28% |
| 2014 | 63.90 | 88.03 | +24.13 | +37.76% | +37.76% |
| 2013 | 48.01 | 63.90 | +15.89 | +33.10% | +33.10% |
| 2012 | 54.38 | 48.01 | -6.37 | -11.71% | -11.71% |
| 2011 | 51.79 | 54.38 | +2.59 | +5.00% | +5.00% |
| 2010 | 41.47 | 51.79 | +10.32 | +24.89% | +24.89% |
| 2009 | 46.29 | 41.47 | -4.82 | -10.41% | -10.41% |
| 2008 | 31.21 | 46.29 | +15.07 | +48.29% | +48.29% |
| 2007 | 25.95 | 31.21 | +5.27 | +20.29% | +20.29% |
| 2006 | 24.80 | 25.95 | +1.15 | +4.66% | +4.66% |
| 2005 | 12.12 | 24.80 | +12.68 | +104.66% | +104.66% |
| 2004 | 10.44 | 12.12 | +1.68 | +16.04% | +16.04% |
| 2003 | 6.25 | 10.44 | +4.18 | +66.91% | +66.91% |
| 2002 | 6.58 | 6.25 | -0.33 | -5.01% | -5.01% |
| 2001 | 43.19 | 6.58 | -36.60 | -84.75% | -84.75% |
| 2000 | 6.09 | 43.19 | +37.09 | +608.72% | +608.72% |
Quarterly Price: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 546 | +2.5% | +90.9% |
| Q1 2026 | 533 | +4.3% | +68.1% |
| Q4 2025 | 510 | +16.3% | +44.7% |
| Q3 2025 | 439 | +53.4% | +24.3% |
| Q2 2025 | 286 | -9.7% | -9.5% |
| Q1 2025 | 317 | -10.2% | +33.7% |
| Q4 2024 | 353 | -0.0% | +60.5% |
| Q3 2024 | 353 | +11.7% | +56.3% |
| Q2 2024 | 316 | +33.4% | +43.2% |
| Q1 2024 | 237 | +7.7% | +8.2% |
| Q4 2023 | 220 | -2.6% | -19.6% |
| Q3 2023 | 226 | +2.3% | +7.0% |
| Q2 2023 | 221 | +0.8% | -7.4% |
| Q1 2023 | 219 | -19.9% | +22.7% |
| Q4 2022 | 273 | +29.5% | +27.9% |
| Q3 2022 | 211 | -11.4% | +12.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt